FIGURE 4.

Therapeutic implications of splicing dysregulation. Overlap of 47 transcripts that are targeted in both elevated eIF4E and SF3B1 mutation, splicing events in the same transcripts can differ leading to distinct outcomes. Data are derived from analysis of AML patients.^{[ 13 ]} Below, pharmacological agents that can reprogram splicing. Note that most SF3B1 targeting compounds bind both the mutant and wildtype forms of SF3B1 and thus influence splicing in either case. Ribavirin, H3B‐8800 and E‐1707 are the only of these compounds tried in human clinical trials published to date.^{[ 89} , ⁹⁰ , ^{91 ]}